Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Real-time Quote. Real-time Tradegate - 10/26 05:13:15 pm
67.995 EUR   -0.77%
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial..
10/25 GLOBAL DIABETIC : Nono Nordisk, Eli Llly, Sanofi, Merk, Tonghua Dong..
10/25SANOFI SA : quaterly earnings release
News SummaryMost relevantAll newsSector news 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
05/04/2012 | 07:35pm CEST
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.


The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).


Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 mr@sanofi.com ir@sanofi.com


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/25 SANOFI : - Sanofi : signs landmark agreement to combat antimicrobial resistance
10/25 GLOBAL DIABETIC NEPHROPATHY (INSULIN : Nono Nordisk, Eli Llly, Sanofi, Merk, Ton..
10/25SANOFI SA : quaterly earnings release
10/21 SANOFI : Genzyme Assigned Patent
10/19 PROMIS NEUROSCIENCES : announces appointment of Dr. Richard Gregory to its Board..
10/18 GLOBAL MENINGOCOCCAL INFECTIONS VACC : Sanofi-Pasteur, Beijing Tiantan Biologica..
10/18 SCHNEIDER ELECTRIC : Three air france apprentices win prizes at altern'up
10/13 REGENERON PHARMACEUTICALS : and Sanofi Announce Positive Dupixent® dupilumab Pha..
10/13 SANOFI : Availability of the Pre-quarterly Results Communication
10/12 GLOBAL KETOPROFEN MARKET 2016 : Sanofi, Boehringer Ingelheim, Zhejiang Jiuzhou, ..
More news
Sector news : Pharmaceuticals - NEC
04:13p GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
04:05pDJGlaxo Profit Jumps on Weaker Pound
09:08a Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/18 In Less Than A Month, Regeneron's Luck Kicks In
10/17 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2016 Update
10/14 WALL STREET BREAKFAST : Big Bank Earnings On Tap
10/14 New Zika zone identified in Miami
10/13 BioCryst Pharmaceuticals To The Rescue With Zika Treatment?
Financials (€)
Sales 2016 36 678 M
EBIT 2016 9 182 M
Net income 2016 5 260 M
Debt 2016 5 715 M
Yield 2016 4,37%
P/E ratio 2016 15,46
P/E ratio 2017 14,26
EV / Sales 2016 2,56x
EV / Sales 2017 2,58x
Capitalization 88 331 M
More Financials
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 25
Average target price 81,6 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.96%96 167
JOHNSON & JOHNSON10.94%311 781
ROCHE HOLDING LTD.-16.53%198 222
PFIZER INC.0.00%195 799
NOVARTIS AG-14.06%191 921
MERCK & CO., INC.17.29%171 305
More Results